



Centre for
Heart Lung Innovation
UBC and St. Paul's Hospital

Centre for Heart Lung Innovation Research in Progress (R.I.P.)



Development of Oncolytic Coxsackievirus B3 for Breast Cancer Therapy

Amirhossein Bahreyni
PhD Student

Dr. Honglin Luo

Monday, Nov 30th, 2020
9:00 – 10:00 a.m.

Zoom Video Conference

(Meeting ID: 618 7697 7684; Passcode: 747268)

“Breast cancer is the leading cause of cancer mortality in women worldwide. Massive side effects observed in current treatments like chemotherapy and lack of appropriate treatment options for patients with chemotherapy-resistant or recurrent cancers, forcing the field toward the rapid development of novel therapies. Oncolytic viruses have emerged as effective procedures for treatment of various malignancies. Our previous research has revealed that miRNA-modified Coxsackievirus B3 (CVB3) exhibits an excellent anti-tumor efficacy against KRAS^{mut} lung adenocarcinoma and TP53^{mut}/RB1^{mut} small cell lung cancer with minimal toxicity. In the current study, we extend our research to breast cancer to evaluate the potency of genetically engineered CVB3 to be applied as a novel treatment against breast tumor, particularly triple-negative breast cancer.”

This event is a Self-Approved Group Learning Activity as defined by the Maintenance Certification Program of the Royal College of Physicians and Surgeons of Canada



a place of mind

THE  LUNG ASSOCIATION™
British Columbia



HEART &
STROKE
FOUNDATION
OF BC & YUKON

Finding answers. For life.